Standard
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count. / Mocroft, Amanda; Reiss, Peter; Kirk, Ole; Mussini, Cristina; Girardi, Enrico; Morlat, Philippe; Stephan, Christoph; De Wit, Stephane; Doerholt, Katja; Ghosn, Jade; Bucher, Heiner C; Lundgren, Jens D; Chene, Genevieve; Miro, Jose M; Furrer, Hansjakob; Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE).
I:
Clinical Infectious Diseases, Bind 51, Nr. 5, 01.09.2010, s. 611-9.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Mocroft, A, Reiss, P
, Kirk, O, Mussini, C, Girardi, E, Morlat, P, Stephan, C, De Wit, S, Doerholt, K, Ghosn, J, Bucher, HC
, Lundgren, JD, Chene, G, Miro, JM, Furrer, H & Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) 2010, '
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count',
Clinical Infectious Diseases, bind 51, nr. 5, s. 611-9.
https://doi.org/10.1086/655761,
https://doi.org/10.1086/655761APA
Mocroft, A., Reiss, P.
, Kirk, O., Mussini, C., Girardi, E., Morlat, P., Stephan, C., De Wit, S., Doerholt, K., Ghosn, J., Bucher, H. C.
, Lundgren, J. D., Chene, G., Miro, J. M., Furrer, H., & Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) (2010).
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count.
Clinical Infectious Diseases,
51(5), 611-9.
https://doi.org/10.1086/655761,
https://doi.org/10.1086/655761Vancouver
Mocroft A, Reiss P
, Kirk O, Mussini C, Girardi E, Morlat P o.a.
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count.
Clinical Infectious Diseases. 2010 sep. 1;51(5):611-9.
https://doi.org/10.1086/655761,
https://doi.org/10.1086/655761Author
Mocroft, Amanda ; Reiss, Peter ; Kirk, Ole ; Mussini, Cristina ; Girardi, Enrico ; Morlat, Philippe ; Stephan, Christoph ; De Wit, Stephane ; Doerholt, Katja ; Ghosn, Jade ; Bucher, Heiner C ; Lundgren, Jens D ; Chene, Genevieve ; Miro, Jose M ; Furrer, Hansjakob ; Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). / Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count. I: Clinical Infectious Diseases. 2010 ; Bind 51, Nr. 5. s. 611-9.
Bibtex
@article{99879f02eb7140029bf2edda39b75689,
title = "Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count",
abstract = "Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.",
keywords = "AIDS-Related Opportunistic Infections, Adult, Anti-HIV Agents, Antifungal Agents, CD4 Lymphocyte Count, Europe, Female, HIV Infections, Humans, Incidence, Male, Middle Aged, Pneumocystis jirovecii, Pneumonia, Pneumocystis, Risk Factors",
author = "Amanda Mocroft and Peter Reiss and Ole Kirk and Cristina Mussini and Enrico Girardi and Philippe Morlat and Christoph Stephan and {De Wit}, Stephane and Katja Doerholt and Jade Ghosn and Bucher, {Heiner C} and Lundgren, {Jens D} and Genevieve Chene and Miro, {Jose M} and Hansjakob Furrer and {Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)}",
year = "2010",
month = sep,
day = "1",
doi = "10.1086/655761",
language = "English",
volume = "51",
pages = "611--9",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",
}
RIS
TY - JOUR
T1 - Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count
AU - Mocroft, Amanda
AU - Reiss, Peter
AU - Kirk, Ole
AU - Mussini, Cristina
AU - Girardi, Enrico
AU - Morlat, Philippe
AU - Stephan, Christoph
AU - De Wit, Stephane
AU - Doerholt, Katja
AU - Ghosn, Jade
AU - Bucher, Heiner C
AU - Lundgren, Jens D
AU - Chene, Genevieve
AU - Miro, Jose M
AU - Furrer, Hansjakob
AU - Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.
AB - Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.
KW - AIDS-Related Opportunistic Infections
KW - Adult
KW - Anti-HIV Agents
KW - Antifungal Agents
KW - CD4 Lymphocyte Count
KW - Europe
KW - Female
KW - HIV Infections
KW - Humans
KW - Incidence
KW - Male
KW - Middle Aged
KW - Pneumocystis jirovecii
KW - Pneumonia, Pneumocystis
KW - Risk Factors
U2 - 10.1086/655761
DO - 10.1086/655761
M3 - Journal article
C2 - 20645862
VL - 51
SP - 611
EP - 619
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 5
ER -
